Masimo Co. (NASDAQ:MASI) Shares Sold by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC reduced its stake in Masimo Co. (NASDAQ:MASI) by 15.9% during the 4th quarter, HoldingsChannel.com reports. The firm owned 10,552 shares of the medical equipment provider’s stock after selling 1,998 shares during the period. Exchange Traded Concepts LLC’s holdings in Masimo were worth $1,744,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. UMB Bank n.a. grew its position in shares of Masimo by 180.9% in the 4th quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 123 shares during the last quarter. Trust Co. of Vermont purchased a new position in shares of Masimo during the fourth quarter worth about $33,000. NBC Securities Inc. increased its position in shares of Masimo by 47.1% during the third quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 73 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Masimo by 133.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 200 shares during the last quarter. Finally, GAMMA Investing LLC boosted its position in shares of Masimo by 136.5% in the 4th quarter. GAMMA Investing LLC now owns 466 shares of the medical equipment provider’s stock valued at $77,000 after purchasing an additional 269 shares during the period. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on MASI shares. Raymond James boosted their price objective on Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a research note on Friday, December 27th. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a research report on Wednesday, January 22nd. Stifel Nicolaus reissued a “buy” rating and set a $190.00 price objective (up from $170.00) on shares of Masimo in a research report on Friday, November 22nd. BTIG Research upped their target price on shares of Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a report on Monday, October 14th. Finally, Piper Sandler raised their price target on Masimo from $180.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, December 18th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $179.67.

Masimo Stock Up 1.3 %

MASI stock opened at $170.24 on Monday. Masimo Co. has a one year low of $101.61 and a one year high of $180.97. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. The company has a fifty day moving average of $170.32 and a 200-day moving average of $142.65. The stock has a market capitalization of $9.11 billion, a PE ratio of 117.41 and a beta of 1.01.

Masimo (NASDAQ:MASI) last announced its quarterly earnings data on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.84 by $0.14. The company had revenue of $504.60 million for the quarter, compared to analyst estimates of $502.87 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.63 EPS. As a group, analysts expect that Masimo Co. will post 4.1 EPS for the current year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.